These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 28133919)

  • 21. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitrectomy After ocriplasmin for VitreOmacular adhesion Or Macular hole (VAVOOM) study.
    Greven MA; Garg S; Chiu B; Shah SP; Wolfe J; Fine HF; Roth DB; Robinson J; Mong J; Hsu J; Regillo C; Ho A; Haller JA
    Br J Ophthalmol; 2016 Sep; 100(9):1211-5. PubMed ID: 26659344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
    Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
    Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
    Khanani AM; Dugel PU; Haller JA; Wagner AL; Lescrauwaet B; Schmidt R; Bennison C
    J Comp Eff Res; 2020 Mar; 9(4):287-305. PubMed ID: 31961196
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
    Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
    Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LONG-TERM OUTCOMES IN PATIENTS WITH VITREOMACULAR TRACTION TREATED WITH A SINGLE INTRAVITREAL INJECTION OF OCRIPLASMIN.
    Tyler L; Singer M; Bell D
    Retin Cases Brief Rep; 2017 Winter; 11(1):34-37. PubMed ID: 26849382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
    Dugel PU; Regillo C; Eliott D
    Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocriplasmin treatment for vitreomacular traction in real life: can the indication spectrum be expanded?
    Manousaridis K; Peter-Reichart S; Mennel S
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1907-1916. PubMed ID: 28681138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COMPARISON OF RESOLUTION OF VITREOMACULAR TRACTION AFTER OCRIPLASMIN TREATMENT OR VITRECTOMY.
    Scholz P; Sitnilska V; Hess J; Becker M; Michels S; Fauser S
    Retina; 2019 Jan; 39(1):180-185. PubMed ID: 29135889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of ocriplasmin on the management of macular holes: assessment of the clinical relevance of ocriplasmin.
    Moisseiev J; Moroz I; Katz G
    JAMA Ophthalmol; 2014 Jun; 132(6):709-13. PubMed ID: 24723009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
    Chatziralli I; Theodossiadis G; Xanthopoulou P; Miligkos M; Sivaprasad S; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Jul; 254(7):1247-56. PubMed ID: 27137631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.